Breast Cancer Following Radiotherapy and Chemotherapy Among Young Women With Hodgkin Disease

Abstract

Treatment of Hodgkin disease (HD) represents one of the major medical successes of the 20th century. Fifty years ago, the typical patient survived only a few years,¹ whereas the current 5-year relative survival rate is 85%.² In the United States alone, approximately 120 000 survivors of HD² are at risk for the serious late sequelae of curative therapies, including the occurrence of new primary cancers.^3,4 Second malignant neoplasms are now the leading cause of death in long-term survivors of HD,^5,6 with breast cancer representing the most frequent solid tumor among women.